{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:52Z","timestamp":1792425772507,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024ky1796"],"award-info":[{"award-number":["2024ky1796"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00415-024-12556-1","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:02:10Z","timestamp":1720526530000},"page":"5911-5915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod"],"prefix":"10.1007","volume":"271","author":[{"given":"Feng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Fen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Hua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3394-0355","authenticated-orcid":false,"given":"Yi-Qing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"issue":"1","key":"12556_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s00018-021-04088-y","volume":"79","author":"P Baudin","year":"2021","unstructured":"Baudin P, Cousyn L, Navarro V (2021) The LGI1 protein: molecular structure, physiological functions and disruption-related seizures. Cell Mol Life Sci 79(1):16. https:\/\/doi.org\/10.1007\/s00018-021-04088-y","journal-title":"Cell Mol Life Sci"},{"key":"12556_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.791014","volume":"12","author":"Y Teng","year":"2022","unstructured":"Teng Y, Li T, Yang Z, Su M, Ni J, Wei M, Shi J, Tian J (2022) Clinical features and therapeutic effects of anti-leucine-rich glioma inactivated 1 encephalitis: a systematic review. Front Neurol 12:791014. https:\/\/doi.org\/10.3389\/fneur.2021.791014","journal-title":"Front Neurol"},{"issue":"10","key":"12556_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1793","volume":"10","author":"P Ghimire","year":"2020","unstructured":"Ghimire P, Khanal UP, Gajurel BP, Karn R, Rajbhandari R, Paudel S, Gautam N, Ojha R (2020) Anti-LGI1, anti-GABABR, and Anti-CASPR2 encephalitides in Asia: a systematic review. Brain Behav 10(10):e01793. https:\/\/doi.org\/10.1002\/brb3.1793","journal-title":"Brain Behav"},{"issue":"3","key":"12556_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/WCO.0000000000001048","volume":"35","author":"BP Trewin","year":"2022","unstructured":"Trewin BP, Freeman I, Ramanathan S, Irani SR (2022) Immunotherapy in autoimmune encephalitis. Curr Opin Neurol 35(3):399\u2013414. https:\/\/doi.org\/10.1097\/WCO.0000000000001048","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"12556_CR5","first-page":"931","volume":"55","author":"Chinese Society of Neuroinfectious Diseases and Cerebrospinal Fluid Cytology","year":"2022","unstructured":"Chinese Society of Neuroinfectious Diseases and Cerebrospinal Fluid Cytology (2022) Chinese expert consensus on the diagnosis and management of autoimmune encephalitis (2022 edition). Chin J Neurol 55(9):931\u2013949","journal-title":"Chin J Neurol"},{"key":"12556_CR6","unstructured":"Arumugham VB, Rayi A (2023) Intravenous Immunoglobulin (IVIG). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. (PMID: 32119333)."},{"issue":"2","key":"12556_CR7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/jca.22043","volume":"38","author":"L Connelly-Smith","year":"2023","unstructured":"Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, Patriquin CJ, Pham HP, Sanchez AP, Schneiderman J, Witt V, Zantek ND, Dunbar NM (2023) Guidelines on the Use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher 38(2):77\u2013278. https:\/\/doi.org\/10.1002\/jca.22043","journal-title":"J Clin Apher"},{"issue":"6","key":"12556_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/pathogens12060817","volume":"12","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Jiang S (2023) Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of Efgartigimod as an FcRn blocker. Pathogens 12(6):817. https:\/\/doi.org\/10.3390\/pathogens12060817","journal-title":"Pathogens"},{"key":"12556_CR9","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","volume":"10","author":"M Pyzik","year":"2019","unstructured":"Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019) The Neonatal Fc Receptor (FcRn): a misnomer? Front Immunol 10:1540. https:\/\/doi.org\/10.3389\/fimmu.2019.01540","journal-title":"Front Immunol"},{"issue":"12","key":"12556_CR10","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE, Sormani MP, Signori A (2023) Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol 30(12):3854\u20133867. https:\/\/doi.org\/10.1111\/ene.15872","journal-title":"Eur J Neurol"},{"issue":"8","key":"12556_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2217\/imt-2022-0298","volume":"15","author":"A Sivadasan","year":"2023","unstructured":"Sivadasan A, Bril V (2023) Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis. Immunotherapy 15(8):553\u2013563. https:\/\/doi.org\/10.2217\/imt-2022-0298","journal-title":"Immunotherapy"},{"key":"12556_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12247-x","author":"J Li","year":"2024","unstructured":"Li J, Wu X, Chu T, Tan X, Wang S, Qu R, Chen Z, Wang Z (2024) The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-024-12247-x. (Epub ahead of print)","journal-title":"J Neurol"},{"issue":"11","key":"12556_CR13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1097\/WNR.0000000000001055","volume":"29","author":"N Ay\u015fit-Altuncu","year":"2018","unstructured":"Ay\u015fit-Altuncu N, Ulusoy C, \u00d6zt\u00fcrk G, T\u00fcz\u00fcn E (2018) Effect of LGI1 antibody-positive IgG on hippocampal neuron survival: a preliminary study. NeuroReport 29(11):932\u2013938. https:\/\/doi.org\/10.1097\/WNR.0000000000001055","journal-title":"NeuroReport"},{"issue":"8","key":"12556_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272277","volume":"17","author":"E Fels","year":"2022","unstructured":"Fels E, Mayeur ME, Wayere E, Vincent C, Malleval C, Honnorat J, Pascual O (2022) Dysregulation of the hippocampal neuronal network by LGI1 auto-antibodies. PLoS ONE 17(8):e0272277. https:\/\/doi.org\/10.1371\/journal.pone.0272277","journal-title":"PLoS ONE"},{"issue":"4","key":"12556_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/mus.27922","volume":"68","author":"J Tavee","year":"2023","unstructured":"Tavee J, Brannagan TH 3rd, Lenihan MW, Muppidi S, Kellermeyer L, Donofrio DP, AANEM (2023) Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle Nerve 68(4):356\u2013374. https:\/\/doi.org\/10.1002\/mus.27922","journal-title":"Muscle Nerve"},{"issue":"7","key":"12556_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jamaneurol.2014.463","volume":"71","author":"SR Irani","year":"2014","unstructured":"Irani SR, Gelfand JM, Bettcher BM, Singhal NS, Geschwind MD (2014) Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy. JAMA Neurol 71(7):896\u2013900. https:\/\/doi.org\/10.1001\/jamaneurol.2014.463","journal-title":"JAMA Neurol"},{"issue":"3","key":"12556_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/jnnp-2021-327302","volume":"93","author":"A Rodriguez","year":"2022","unstructured":"Rodriguez A, Klein CJ, Sechi E, Alden E, Basso MR, Pudumjee S, Pittock SJ, McKeon A, Britton JW, Lopez-Chiriboga AS, Zekeridou A, Zalewski NL, Boeve BF, Day GS, Gadoth A, Burkholder D, Toledano M, Dubey D, Flanagan EP (2022) LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry 93(3):309\u2013315. https:\/\/doi.org\/10.1136\/jnnp-2021-327302","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"12556_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jneuroim.2013.10.005","volume":"265","author":"YW Shin","year":"2013","unstructured":"Shin YW, Lee ST, Shin JW, Moon J, Lim JA, Byun JI, Kim TJ, Lee KJ, Kim YS, Park KI, Jung KH, Lee SK, Chu K (2013) VGKC-complex\/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 265(1\u20132):75\u201381. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.10.005","journal-title":"J Neuroimmunol"},{"issue":"10","key":"12556_CR19","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N (2018) Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J Clin Invest 128(10):4372\u20134386. https:\/\/doi.org\/10.1172\/JCI97911","journal-title":"J Clin Invest"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12556-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12556-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T08:19:41Z","timestamp":1725524381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12556-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12556"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12556-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Ethics Committee of Enze Hospital, Taizhou Enze Medical Center (Group) approved this study with an approving number of K20240407 and waived the formal informed consent form as the patient had previously signed the paper titled \"informed consent form for biological sample providers\".","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}